Technical Analysis for ANNX - Annexon, Inc.

Grade Last Price % Change Price Change
F 5.16 -5.49% -0.30
ANNX closed down 5.49 percent on Wednesday, November 20, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish -5.49%
NR7 Range Contraction -5.49%
Lower Bollinger Band Walk Weakness -5.49%
Wide Bands Range Expansion -5.49%
Below Lower BB Weakness -5.49%

   Recent Intraday Alerts

Alert Time
Down 1 ATR about 16 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Possible NR7 about 18 hours ago
Down 5% about 21 hours ago
Down 3% about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Annexon, Inc. Description

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Immune System Eye Monoclonal Antibody Antibody Ophthalmic Biomarkers Autoimmunity Degenerative Disease Platform Technology Complement System Neurodegenerative Disorders Intravitreal Administration

Is ANNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.4
52 Week Low 2.27
Average Volume 1,453,832
200-Day Moving Average 5.83
50-Day Moving Average 6.86
20-Day Moving Average 6.86
10-Day Moving Average 6.33
Average True Range 0.38
RSI (14) 20.63
ADX 28.84
+DI 10.00
-DI 43.32
Chandelier Exit (Long, 3 ATRs) 6.61
Chandelier Exit (Short, 3 ATRs) 6.17
Upper Bollinger Bands 8.36
Lower Bollinger Band 5.36
Percent B (%b) -0.07
BandWidth 43.76
MACD Line -0.39
MACD Signal Line -0.14
MACD Histogram -0.2497
Fundamentals Value
Market Cap 403.89 Million
Num Shares 78.3 Million
EPS -1.81
Price-to-Earnings (P/E) Ratio -2.85
Price-to-Sales 0.00
Price-to-Book 2.72
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.78
Resistance 3 (R3) 5.81 5.64 5.68
Resistance 2 (R2) 5.64 5.48 5.62 5.64
Resistance 1 (R1) 5.40 5.38 5.31 5.37 5.61
Pivot Point 5.22 5.22 5.18 5.21 5.22
Support 1 (S1) 4.98 5.06 4.90 4.95 4.71
Support 2 (S2) 4.81 4.97 4.79 4.68
Support 3 (S3) 4.57 4.81 4.64
Support 4 (S4) 4.54